Wednesday, December 6, 2023, 7:15 PM – 9:15 PM CT (8:15 PM – 10:15 PM ET) | San Antonio, Texas
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Localized HER2-Negative Breast Cancer
Part 2 of a 3-Part CME Satellite Symposium Series in Partnership with the 2023 San Antonio Breast Cancer Symposium®
Event Details
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting
Meeting Room
Grand Ballroom G-M (Third Floor)
This event will also be webcast live.
Please see Registration tab for details.
Harold J Burstein, MD, PhD
Institute Physician
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Matthew P Goetz, MD
Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Director, Mayo Clinic Breast Cancer SPORE
Mayo Clinic
Rochester, Minnesota
Sara A Hurvitz, MD, FACP
Professor
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Head, Division of Hematology/Oncology
UW Medicine
Seattle, Washington
Joyce O’Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Lajos Pusztai, MD, DPhil, FASCO
Professor of Medicine
Scientific Co-Director of the Center for Breast Cancer
Co-Leader, Genetics, Genomics
and Epigenetics Program
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
This symposium is sponsored by Research To Practice and supported by grants from AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Lilly, Merck, Natera Inc, Novartis, and TerSera Therapeutics LLC. This is not an official program of the San Antonio Breast Cancer Symposium®.
Agenda
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting
MODULE 1: Role of Genomic Assays in Treatment Decision-Making for Localized ER-Positive, HER2-Negative Breast Cancer — Dr Goetz
- Clinicopathologic factors influencing the decision to consult a genomic classifier to guide decision-making for patients with ER-positive, HER2-negative localized breast cancer
- Long-term data from the TAILORx study assessing the use of 21-gene Recurrence Score® (RS) results to guide decisions about adjuvant chemotherapy for node-negative, ER-positive, HER2-negative localized breast cancer
- Major findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative breast cancer with 1 to 3 positive lymph nodes and a 21-gene RS of ≤25
- Other recent studies informing the use of the 21-gene RS to guide neoadjuvant and adjuvant treatment decision-making
- Development and validation of the RSClin educational tool to individualize therapy for patients with localized, node-negative, ER-positive, HER2-negative disease
- Available data sets with and current clinical utility of other genomic assays (eg, MammaPrint®, EndoPredict®, Prosigna®, Breast Cancer Index®) for ER-positive localized breast cancer
MODULE 2: Integration of Ovarian Function Suppression (OFS) into the Management of Breast Cancer in Premenopausal Patients — Dr Burstein
- Long-term follow-up from key studies supporting the addition of OFS/ablation to standard adjuvant hormonal therapy for premenopausal patients with ER-positive breast cancer
- Published data sets evaluating OFS with a gonadotropin-releasing hormone agonist (GnRHa) as a means to prevent chemotherapy-associated premature ovarian insufficiency and preserve fertility in premenopausal patients with breast cancer
- Current clinical role of OFS/ablation in therapy for high-risk or average/low-risk breast cancer; individualized selection of a specific hormonal therapy approach
- Optimal timing of initiation of GnRHa therapy in patients with breast cancer receiving cytotoxic therapy
- Appropriate duration of GnRHa treatment; published studies exploring the use of OFS for fewer than 5 years
MODULE 3: Role of CDK4/6 Inhibitors and Other Novel Agents in Therapy for ER-Positive Localized Breast Cancer — Dr Hurvitz
- Improved rates of pathologic complete response with the addition of pembrolizumab and nivolumab, respectively, to neoadjuvant chemotherapy for high-risk, ER-positive, HER2-negative breast cancer in the KEYNOTE-756 and CheckMate 7FL studies
- Extended follow-up from the Phase III monarchE trial evaluating abemaciclib with standard adjuvant hormonal therapy for ER-positive, HER2-negative, high-risk localized breast cancer
- Recent expansion of the indication for adjuvant abemaciclib; identification of appropriate patients for this strategy
- Available data from the Phase III NATALEE trial evaluating the addition of ribociclib to adjuvant endocrine therapy for ER-positive, HER2-negative localized breast cancer
- Early data with and ongoing studies evaluating CDK4/6 inhibitors as neoadjuvant therapy for localized ER-positive breast cancer
- Current role of olaparib as adjuvant treatment for ER-positive, BRCA-mutated localized breast cancer; selection between a CDK4/6 inhibitor and olaparib for patients eligible for both therapies
MODULE 4: Optimizing the Use of Neoadjuvant and Adjuvant Therapy for Triple-Negative Breast Cancer (TNBC) — Dr O’Shaughnessy
- Recommended approaches to biomarker assessment for patients with localized TNBC
- Available data from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized TNBC
- FDA approval of (neo)adjuvant pembrolizumab; selection of appropriate candidates and practical implementation
- Key findings among patients with TNBC from the Phase III OlympiA trial assessing adjuvant olaparib versus placebo for BRCA-mutated, high-risk, HER2-negative breast cancer
- Current clinical role of adjuvant olaparib for patients with high-risk TNBC and a germline BRCA1/2 mutation
- Available data with and ongoing studies evaluating other PARP inhibitors or immune checkpoint inhibitors as a component of neoadjuvant or adjuvant therapy for TNBC
MODULE 5: Emerging Role of Circulating Tumor DNA (ctDNA) Evaluation in the Management of Breast Cancer — Dr Pusztai
- Rationale for the use of ctDNA monitoring for localized breast cancer
- Available data with ctDNA monitoring during and after neoadjuvant therapy to better risk-stratify patients and potentially inform further decision-making
- Published findings with ctDNA testing to monitor for disease recurrence in patients with localized breast cancer
- Potential clinical impact of earlier detection of breast cancer relapse than is feasible with current standard follow-up
- Optimal source material and method for detecting ctDNA in patients with localized breast cancer
- Active studies examining the clinical utility of ctDNA testing for guiding treatment decisions in breast cancer
CE Information
Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
Learning Objectives
At the conclusion of this activity, participants should be able to
- Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive, HER2-negative breast cancer.
- Comprehend available research findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the current and future role of these agents as components of adjuvant treatment.
- Review available clinical research findings documenting the efficacy of the addition of gonadotropin-releasing hormone agonists to standard adjuvant endocrine interventions for premenopausal patients with ER-positive breast cancer, and identify appropriate candidates for this strategy.
- Recognize the potential for chemotherapy-induced premature ovarian insufficiency associated with various cytotoxic agents for breast cancer, and assess the effectiveness and possible role of various interventions in preserving ovarian hormone production and facilitating successful childbirth.
- Consider available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibody-based approaches for localized triple-negative breast cancer, and develop a plan to integrate this therapeutic strategy into current treatment algorithms.
- Appraise published efficacy and safety data with PARP inhibitors for localized breast cancer in patients harboring BRCA1/2 mutations, and consider how to optimally incorporate these agents in the curative setting where appropriate.
- Evaluate the potential benefits of measuring circulating tumor DNA to assess the absence or presence of molecular residual disease during and after treatment for localized breast cancer, and consider the current and future utility of this strategy in clinical practice.
- Assess early data with and ongoing clinical trials evaluating novel agents and treatment strategies under development for localized ER-positive and triple-negative breast cancer.
CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Burstein has no relevant conflicts of interest to disclose. The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
Dr Goetz — Consulting Agreements (Fees to Institution): ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Blueprint Medicines, Lilly, RNA Diagnostics, Sanofi, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sermonix Pharmaceuticals; Data and Safety Monitoring Board/Committee: Seagen Inc; Moderator Service: Curio Science; Nonrelevant Financial Relationship: Clinical Education Alliance, Engage Health Media, JNCCN 360, Medscape, MJH Life Sciences, Total Health Conferencing. Dr Hurvitz — Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, GSK, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc. Dr O’Shaughnessy — Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Synthon, Theralink, Veru; Nonrelevant Financial Relationship: prIME Oncology. Dr Pusztai — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exact Sciences Corporation, Merck, Natera Inc, Pfizer Inc, Predicine; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exact Sciences Corporation, Merck, Natera Inc, Pfizer Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Lilly, Merck, Natera Inc, Novartis, and TerSera Therapeutics LLC.
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom G-M (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2023 San Antonio Breast Cancer Symposium is taking place.
Registration
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2023 San Antonio Breast Cancer Symposium®.
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our Onsite Registration Desk will be open at 6:45 PM CT on Wednesday, December 6th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom G-M (Third Floor) of the Marriott Rivercenter hotel (101 Bowie St) within walking distance of the Henry B Gonzalez Convention Center. We will accommodate as many onsite attendees as possible. Seating will be prioritized for clinicians in practice.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
NOTICE: Registration for this event is independent of registration for the SABCS Conference.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.